Filing Details

Accession Number:
0001209191-19-017932
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-03-07 21:44:28
Reporting Period:
2019-02-14
Accepted Time:
2019-03-07 21:44:28
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1668243 Urogen Pharma Ltd. URGN Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1764139 Stephen Mullennix C/O Urogen Pharma Ltd.
9 Ha?Ta?Asiya Street
Ra?Anana L3 4365007
Chief Operating Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Acquisiton 2019-02-14 7,034 $0.00 7,034 No 4 M Direct
Ordinary Shares Disposition 2019-02-14 2,804 $37.30 4,230 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Ordinary Shares Restricted Stock Units Disposition 2019-02-14 7,034 $0.00 7,034 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
14,073 No 4 M Direct
Footnotes
  1. Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer.
  2. Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.
  3. The reporting person was granted restricted stock units ("RSUs") on March 7, 2018, June 4, 2018 and October 28, 2018 representing 21,107 ordinary shares in the aggregate. 1/3rd of the RSUs vested on February 14, 2019 (with the issuance of the underlying ordinary shares delayed until March 5, 2019), with the balance vesting in equal quarterly installments thereafter over a period of two years.